Targeting heart failure therapeutics: a historical perspective.
This article reviews information on the role of genetic variability in the development, progression, and treatment of heart failure. It focuses primarily on genetic variation in neurohormonal systems, where adrenergic receptors and the renin-angiotensin-aldosterone system are the two most explored areas. The article also reviews the endothelin system and natriuretic peptides. Clinical trial design issues are examined, and suggestions for pharmacogenomic clinical trials are presented. Finally, lessons from the oncology field and the changing regulatory landscape are discussed.
Murphy
Guinevere A
GA
ARCA biopharma, Inc, 8001 Arista Place, Suite 200, Broomfield, CO 80021, USA.
Fiuzat
Mona
M
Bristow
Michael R
MR
D000959:Antihypertensive Agents / Q000627:therapeutic use; D009320:Atrial Natriuretic Factor / Q000187:drug effects / Q000235:genetics; D002316:Cardiotonic Agents / Q000627:therapeutic use; D016232:Endothelins / Q000187:drug effects / Q000235:genetics; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D011110:Polymorphism, Genetic; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000235:genetics; D011943:Receptors, Adrenergic, beta / Q000187:drug effects / Q000235:genetics; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000235:genetics
D000959:Antihypertensive Agents; D002316:Cardiotonic Agents; D016232:Endothelins; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D009320:Atrial Natriuretic Factor